CN107296954A - 一种层粘连蛋白创面保护膜 - Google Patents
一种层粘连蛋白创面保护膜 Download PDFInfo
- Publication number
- CN107296954A CN107296954A CN201710429812.1A CN201710429812A CN107296954A CN 107296954 A CN107296954 A CN 107296954A CN 201710429812 A CN201710429812 A CN 201710429812A CN 107296954 A CN107296954 A CN 107296954A
- Authority
- CN
- China
- Prior art keywords
- laminin
- capsule
- parts
- wound
- micro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 claims abstract description 36
- 239000002775 capsule Substances 0.000 claims abstract description 32
- 239000003094 microcapsule Substances 0.000 claims abstract description 32
- 239000011162 core material Substances 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 210000002381 plasma Anatomy 0.000 claims abstract description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 9
- 239000000661 sodium alginate Substances 0.000 claims abstract description 9
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 9
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 8
- 235000010410 calcium alginate Nutrition 0.000 claims abstract description 8
- 239000000648 calcium alginate Substances 0.000 claims abstract description 8
- 229960002681 calcium alginate Drugs 0.000 claims abstract description 8
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims abstract description 8
- 229960001631 carbomer Drugs 0.000 claims abstract description 8
- 239000011159 matrix material Substances 0.000 claims abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000011780 sodium chloride Substances 0.000 claims abstract description 6
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 239000000725 suspension Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- -1 element Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 239000002385 cottonseed oil Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims 1
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 55
- 206010052428 Wound Diseases 0.000 abstract description 53
- 230000000694 effects Effects 0.000 abstract description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract description 6
- 229940068984 polyvinyl alcohol Drugs 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 239000007921 spray Substances 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- 208000004210 Pressure Ulcer Diseases 0.000 abstract 1
- 206010040943 Skin Ulcer Diseases 0.000 abstract 1
- 201000006994 chronic ulcer of skin Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 10
- 210000002469 basement membrane Anatomy 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 206010048038 Wound infection Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 206010011732 Cyst Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000009087 cell motility Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000004382 potting Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
一种层粘连蛋白创面保护膜是以动物血浆层粘连蛋白为主要成分，加有无菌生理盐水以及药用辅料组成。其具体成分重量份配比为：动物血浆层粘连蛋白微囊1‑30份，成膜基质0.1‑30份，保湿剂1‑10份，无菌生理盐水补足至100份。所述的动物血浆层粘连蛋白微囊是以溶于水的层粘连蛋白溶液为囊心物，由囊材包裹的微囊；所述的成膜基质为聚乙烯醇、卡波姆、海藻酸钠、海藻酸钙中的一种或几种。本发明将层粘连蛋白制成微囊，可维持其生物活性的同时，延长保存期。本发明可制成水剂或凝胶剂型，制备工艺简单，适合大规模生产。本发明产品可直接喷、涂于烧伤、创伤、糖尿病烂足、褥疮及其它皮肤慢性溃疡等患者的伤口，使用方便，疗效好。
Description
技术领域
本发明涉及生物医药领域，尤其涉及一种层粘连蛋白创面保护膜。
背景技术
众所周知，人体一旦遭受创伤，伤口如果护理不周就会造成伤口感染，严重者可能化脓，经久不愈，甚至引发全身感染、气性坏疽、破伤风等危及生命。伤口感染是病原微生物通过伤口侵入机体后，在体内生长、繁殖，致机体的正常功能、代谢、组织结构受到破坏，引起组织损伤性病变的病理反应。目前用的最多的抗感染类药物就是抗生素类。但抗生素类药物会引起过敏反应；耐药性；白细胞、红细胞、血小板减少；神经系统损害；且长期或大剂量使用广谱抗生素，由于体内敏感细菌被抑制，而未被抑制的细菌以及真菌即趁机大量繁殖，引起菌群失调而致病，因此，应严格掌握抗生素的适应症，避免不合理滥用抗生素。伤口的治疗原则应是尽快缩小创面、防止再损伤和促进组织再生，避免一些不利因素，创造有利条件促进组织再生修复。
层粘连蛋白(laminin，LN)是一种大型的糖蛋白，与IV型胶原一起构成基膜，是胚胎发育中出现最早的细胞外基质成分。所谓基膜是指上皮细胞下方一层柔软的特化的细胞外基质，也存在于肌肉、脂肪和许旺细胞周围，它不仅仅起保护和过滤作用，还决定细胞的极性，影响细胞的代谢、存活、迁移、增殖和分化。在机体生命活动中，LN作为基膜的主要结构成分对基膜的组装起关键作用，在细胞表面形成网络结构并将细胞固定在基膜上；并与多种基底膜成分结合，调节细胞生长和分化，也参与机体众多病理过程。它可能通过巨噬细胞、淋巴细胞等细胞成分释放生长因子，促进成纤维细胞增殖及合成胶原纤维，加重纤维化病变程度， LN参与纤维化的全过程；在细胞发育过程中刺激细胞粘着、细胞运动；LN还能够刺激胚胎中神经轴的生长，并促进成年动物的神经损伤后重生长和再生；大量的研究和临床应用已证明，LN在伤口的修复和愈合中起着十分重要的作用，对难愈合伤口的愈合治疗中具有显著的效果，是促进难愈合创面的关键物质。
微胶囊技术利用天然的或合成的高分子材料，通过化学法、物理法或物理化学法将固体、液体甚至是气体等核心物质包囊成直径为1-5000μm的一种具有半透性或密封囊膜的微小囊状物的技术。通常把构成微胶囊的外壳材料称为“囊材”，把包在微胶囊内部的物质称为“芯材”。药物微胶囊化后可将活细胞或生物活性物质包裹，囊膜有隔离外界与药物接触作用，可防止药物氧化、水解和挥发，提高药物的稳定性；可控制调节释放能力，由于微胶囊膜为半透性膜，故可以改变条件，对芯材的释放时间和速率加以控制，使微胶囊的核心物质以一定的速率逐渐向外释放，延长药物作用时间等。
医药级聚乙烯醇是一种极安全的高分子有机物，对人体无毒，无副作用，具有良好的生物相容性，尤其在医疗中如其水性凝胶在眼科、伤口敷料和人工关节方面的有广泛应用，同时聚乙烯醇薄膜在药用膜，人工肾膜等方面也有使用。其安全性可以从用于伤口皮肤修复，和眼部滴眼液产品可见一斑。其中一些型号也常被用在化妆品中的面膜、洁面膏、化妆水及乳液中，是一种常用的安全性成膜剂。卡波姆是以季戊四醇等与丙烯酸交联得到的丙烯酸交联树脂，是一类非常重要的流变调节剂，中性环境下卡波姆体系是极好的凝胶基质，表观晶莹，手感润滑，非常适合用来制备霜或凝胶剂，同时由于工艺简单，稳定性好，用后感觉舒适，因此在局部给药中，特别是在皮肤及眼用凝胶剂中具有广泛应用。海藻酸钠、海藻酸钙海藻酸钙是从海藻植物中提炼的多糖物质。当它用于伤口接触层时，它与伤口之间相互作用，会产生海藻酸钠、海藻酸钙凝胶。这种凝胶是亲水性的，可使氧气通过而细菌不能通过，并促进新组织的生长。聚乙烯醇、卡波姆、海藻酸钠、海藻酸钙会在创口表面形成凝胶层，对创面起到一定的保护作用，并使创面保持一定的湿度，温度，为创面的愈合创造一个良好的微环境，促使创口及早愈合。
发明内容
本发明的目的在于提供一种可保湿抑菌、疗效稳定、无副作用、用药方便、利于生产、便于保存和运输的层粘连蛋白制剂，该制剂可在创面及伤口形成一层生物蛋白保护膜，这种生物膜可使氧气通过而细菌不能通过，使创面保持一定的湿度，温度，并促进新组织的生长，能够增强细胞或组织修复、再生或维持，可加速患者烧伤、创伤、溃疡等伤口的愈合。
基于上述目的，本发明采取如下技术方案：
本发明的层粘连蛋白创面保护膜是以动物血浆层粘连蛋白为主要成分，加有无菌生理盐水以及药用辅料组成。其具体成分重量份配比为：动物血浆层粘连蛋白微囊1-30份，成膜基质0.1-30份，保湿剂1-10份，无菌生理盐水补足至100份。
其中所述层粘连蛋白微囊是以层粘连蛋白溶液为囊心物，由囊材包裹的微囊；其囊材的浓度为1-8％，芯材与囊材的比例为1∶1～6。
所述囊材为甲基纤维素、乙基纤维素、羧甲基纤维素等纤维素的衍生物、卵磷脂、胆固醇、十八胺、海藻酸盐、聚赖氨酸、脱乙酰几丁酯、蔗糖脂肪酸酯、甘油酯、磷脂酰胆碱等中的一种或两种。
所述一种纤连蛋白微囊制剂的制备方法，其特征在于包括以下步骤：
(1)用无水乙醇作溶剂配制成囊材浓度为1-8％的囊材溶液；
(2)将层粘连蛋白与囊材按1∶1～6的比例加入上述囊材溶液中，在常温、压力40MPa 条件下，均质两次，得到均匀的混悬液；
(3)将上述制备得到的混悬液先放于-20℃冰箱中冷冻，冷冻6h～12h，再转移至真空冷冻干燥机中进行干燥10h～16h，得到的干燥粉末即为层粘连蛋白微胶囊。
所述的成膜基质为聚乙烯醇、卡波姆、海藻酸钠、海藻酸钙中的一种或几种。
所述的保湿剂为医用甘油或椰子油、棉籽油、花生油、芝麻油等植物油中的一种。
LN作为基膜的主要结构成分对基膜的组装起关键作用，在细胞表面形成网络结构并将细胞固定在基膜上，在伤口处刺激细胞粘着、细胞运动、上皮细胞的迁移和增殖以修复伤口，加速伤口愈合，减轻愈合疤痕。由于LN分子在进化的过程中保守性很强，各种动物液体中的LN具有非常相似的结构、性质和生物学功能，不同来源的LN可以相互替代使用。本发明采用低温冷冻干燥法将层粘连蛋白制成微囊，囊膜有隔离外界与药物接触作用，可以有效地保持物料原有的天然色泽、风味以及形态，改变其易受外界环境影响而失去活性、提高药物的稳定性；可控制调节释放能力，由于微胶囊膜为半透性膜，故可以改变条件，对芯材的释放时间和速率加以控制，使微胶囊的核心物质以一定的速率逐渐向外释放，延长药物作用时间等。聚乙烯醇、卡波姆、海藻酸钠、海藻酸钙会在创口表面形成凝胶层，这种凝胶是亲水性的，可使氧气通过而细菌不能通过，并促进新组织的生长。甘油或植物油具有润肤并对 LN的生物活性有一定的保护作用。
本发明层粘连蛋白创面保护膜是以动物血浆LN为主要原料，添加成膜基质和保湿剂，可在创口表面形成一层生物蛋白保护膜，对创面起到一定的保护作用，避免伤口感染，并使创面保持一定的湿度，温度，为创面的愈合创造一个良好的微环境，促使创口及早愈合。
本发明可制成水剂或凝胶剂型。本发明产品可直接喷、涂于烧伤、创伤、溃疡等患者的伤口。
本发明产品具有以下优势：
(1)LN可能通过巨噬细胞、淋巴细胞等细胞成分释放生长因子，促进成纤维细胞增殖及合成胶原纤维，为伤口的修复提供良好的细胞外环境，在伤口处刺激细胞粘着、细胞运动、上皮细胞的迁移和增殖以修复伤口，增强细胞或组织修复、再生或维持，可加速患者烧伤、创伤、溃疡等伤口的愈合，减轻愈合疤痕。
(2)本产品可在创口表面形成一层生物蛋白保护膜，可使氧气通过而细菌不能通过，对创面起到一定的保护作用，避免伤口感染，并使创面保持一定的湿度，温度，为创面的愈合创造一个良好的微环境，促使创口及早愈合。
(3)本发明采用低温冷冻干燥法将层粘连蛋白制成微囊，可以有效地保持物料原有的天然色泽、风味以及形态，改变其易受外界环境影响而失去活性、不方便运输和保存的缺点，有利于运输、保藏和使用。
(4)本发明将层粘连蛋白制成微囊，由于微胶囊膜为半透性膜，故可以改变条件，对芯材的释放时间和速率加以控制，使微胶囊的核心物质以一定的速率逐渐向外释放，可控制调节释放能力，延长药物作用时间。
(5)本层粘连蛋白创面保护膜中所用辅料成膜基质和保湿剂可保持伤口湿润，防止干裂，同时可保持LN的生物活性，最大限度的发挥LN创面修复细胞作用，提高LN的生物利用度，功效好，无副作用，属于纯天然生物制品。
(6)本产品中制剂材料来源广泛，成本低廉，制备工艺简单，具有非常好的应用前景。
具体实施方式
下面结合具体实施例，对本发明作进一步的说明。
实施例1 凝胶剂
1、动物血浆层粘连蛋白微囊其囊材的浓度为8％，芯材与囊材的比例为1∶6；具体制备方法包括以下步骤：
(1)用无水乙醇作溶剂配制成浓度为8％的羧甲基纤维素囊材溶液；
(2)将层粘连蛋白与囊材按1∶6的比例加入上述囊材溶液中，在常温、压力40MPa条件下，均质两次，得到均匀的混悬液；
(3)将上述制备得到的混悬液先放于-20℃冰箱中冷冻，冷冻12h，再转移至真空冷冻干燥机中进行干燥16h，得到的干燥粉末即为层粘连蛋白微囊。
2、取上述步骤1中制备的动物血浆层粘连蛋白微囊30份，卡波姆0.3份，海藻酸钠15 份，医用甘油5份，无菌生理盐水补足至100份。搅拌使乳化均匀，制成凝胶剂。
3、按规格要求罐封于无菌塑料瓶内，即为层粘连蛋白创面保护膜产品。
实施例2：水剂
1、动物血浆层粘连蛋白微囊其囊材的浓度为3％，芯材与囊材的比例为1∶2；具体制备方法包括以下步骤：
(1)用无水乙醇作溶剂配制成浓度为3％的甘油酯囊材溶液；
(2)将层粘连蛋白与囊材按1∶2的比例加入上述囊材溶液中，在常温、压力40MPa条件下，均质两次，得到均匀的混悬液；
(3)将上述制备得到的混悬液先放于-20℃冰箱中冷冻，冷冻10h，再转移至真空冷冻干燥机中进行干燥12h，得到的干燥粉末即为层粘连蛋白微囊。
2、取上述步骤1中制备的动物血浆层粘连蛋白微囊3份，聚乙烯醇2份、海藻酸钠1份和医用甘油3份加入91份无菌生理盐水中充分混合，得到均匀的混合溶液；
3、将步骤2得到的混合溶液经0.22μm滤膜除菌，按规格要求罐封于无菌塑料瓶内，即为层粘连蛋白创面保护膜产品。按药典无菌检测方法要求检测，产品应无菌。
4、应用时直接喷涂到处理干净的伤口处。
本发明的产品经临床应用试验，获得良好效果。经专业检验机构检测，其理化指标和毒性试验，均符合卫生要求。
Claims (6)
1.一种层粘连蛋白创面保护膜，其特征在于：它是以动物血浆层粘连蛋白为主要成分，加有无菌生理盐水以及药用辅料组成，其具体成分重量份配比为：动物血浆层粘连蛋白微囊1-30份，成膜基质0.1-30份，保湿剂1-10份，无菌生理盐水补足至100份。
2.根据权利要求1所述的一种层粘连蛋白创面保护膜，其特征在于：所述层粘连蛋白微囊是以层粘连蛋白溶液为囊心物，由囊材包裹的微囊；其囊材的浓度为1-8％，芯材与囊材的比例为1∶1～6。
3.根据权利要求1所述的层粘连蛋白创面保护膜，其特征在于：所述囊材为甲基纤维素、乙基纤维素、羧甲基纤维素等纤维素的衍生物、卵磷脂、胆固醇、十八胺、海藻酸盐、聚赖氨酸、脱乙酰几丁酯、蔗糖脂肪酸酯、甘油酯、磷脂酰胆碱等中的一种或两种。
4.根据权利要求2所述的一种层粘连蛋白创面保护膜，其特征在于：所述一种层粘连蛋白微囊制剂的制备方法，其特征在于包括以下步骤：
(1)用无水乙醇作溶剂配制成囊材浓度为1-8％的囊材溶液；
(2)将层粘连蛋白与囊材按1∶1～6的比例加入上述囊材溶液中，在常温、压力40MPa条件下，均质两次，得到均匀的混悬液；
(3)将上述制备得到的混悬液先放于-20℃冰箱中冷冻，冷冻6h～12h，再转移至真空冷冻干燥机中进行干燥10h～16h，得到的干燥粉末即为层粘连蛋白微胶囊。
5.根据权利要求1所述的一种层粘连蛋白创面保护膜，其特征在于：所述成膜基质为聚乙烯醇、卡波姆、海藻酸钠、海藻酸钙中的一种或几种。
6.根据权利要求1所述的层粘连蛋白创面保护膜，其特征在于：所述的保湿剂为医用甘油或椰子油、棉籽油、花生油、芝麻油等植物油中的一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710429812.1A CN107296954A (zh) | 2017-06-09 | 2017-06-09 | 一种层粘连蛋白创面保护膜 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710429812.1A CN107296954A (zh) | 2017-06-09 | 2017-06-09 | 一种层粘连蛋白创面保护膜 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107296954A true CN107296954A (zh) | 2017-10-27 |
Family
ID=60134776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710429812.1A Pending CN107296954A (zh) | 2017-06-09 | 2017-06-09 | 一种层粘连蛋白创面保护膜 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107296954A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110755281A (zh) * | 2019-11-16 | 2020-02-07 | 许帅辉 | 一种皮肤修复及护理组合物及其制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010002261A1 (en) * | 1994-12-02 | 2001-05-31 | Government Of The United States Of America National Aeronautics & Space Administration | Microencapsulated bioactive agents and method of making |
| US20030021843A1 (en) * | 1999-12-28 | 2003-01-30 | Ajinomoto Co. Inc | Antidiabetic preparation for oral administration |
| WO2008040230A1 (fr) * | 2006-09-15 | 2008-04-10 | Zhengzhou Tongyuan Biotechnology Co., Ltd. | Consolidant à base de fibronectine agissant sur les traumatismes et les ulcères |
| US20100239556A1 (en) * | 2006-12-13 | 2010-09-23 | TGR BioScience Pty Ltd. | Promoting ecm production by fibroblast cells and/or promoting migration of fibroblast cells in a biological system |
| US20140113347A1 (en) * | 2010-12-16 | 2014-04-24 | Cellprotect Biotecnologia Ltda-Me | Biopolymer Composition for Encapsulating Cells, Method for Producing a Biopolymer Composition for Encapsulating Cells, Method for Promoting Cell Cytoprotection and Use of a Biopolymer Composition for Encapsulating Cells |
| CN104688721A (zh) * | 2014-10-11 | 2015-06-10 | 黄萍 | 一种含紫杉醇脂质体的抗类风湿性关节炎药物凝胶剂及其制备方法 |
-
2017
- 2017-06-09 CN CN201710429812.1A patent/CN107296954A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010002261A1 (en) * | 1994-12-02 | 2001-05-31 | Government Of The United States Of America National Aeronautics & Space Administration | Microencapsulated bioactive agents and method of making |
| US20030021843A1 (en) * | 1999-12-28 | 2003-01-30 | Ajinomoto Co. Inc | Antidiabetic preparation for oral administration |
| WO2008040230A1 (fr) * | 2006-09-15 | 2008-04-10 | Zhengzhou Tongyuan Biotechnology Co., Ltd. | Consolidant à base de fibronectine agissant sur les traumatismes et les ulcères |
| US20100239556A1 (en) * | 2006-12-13 | 2010-09-23 | TGR BioScience Pty Ltd. | Promoting ecm production by fibroblast cells and/or promoting migration of fibroblast cells in a biological system |
| US20140113347A1 (en) * | 2010-12-16 | 2014-04-24 | Cellprotect Biotecnologia Ltda-Me | Biopolymer Composition for Encapsulating Cells, Method for Producing a Biopolymer Composition for Encapsulating Cells, Method for Promoting Cell Cytoprotection and Use of a Biopolymer Composition for Encapsulating Cells |
| CN104688721A (zh) * | 2014-10-11 | 2015-06-10 | 黄萍 | 一种含紫杉醇脂质体的抗类风湿性关节炎药物凝胶剂及其制备方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110755281A (zh) * | 2019-11-16 | 2020-02-07 | 许帅辉 | 一种皮肤修复及护理组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107185031B (zh) | 一种具有生物活性的医用敷料及其制备方法 | |
| AU2020101591A4 (en) | A thermosensitive gel, preparation method and application thereof | |
| WO2015176558A1 (zh) | 一种天然维生素c和鱼鳞胶原蛋白肽的组合物及其制备方法 | |
| CN101491498A (zh) | 一种aFGF脂质体、制备方法及其应用 | |
| CN101648018A (zh) | 一种治疗眼科炎症的中药组合物及其用途 | |
| KR100828494B1 (ko) | 피부주름개선용 화장품 에센스 조성물 및 그의 조성방법 | |
| Al-Hatamleh et al. | Applications of alginate-based nanomaterials in enhancing the therapeutic effects of bee products | |
| CN103083712A (zh) | 掺入有干细胞或其它生物活性物质的外科敷料 | |
| US20040087544A1 (en) | Pharmaceutical compositions of topic use, applied in treatment of skin and/or mucous injuries use of compositions in treatment of skin and/or mucous injuries and use of compounds in treatment of skin and/or mucous injuries | |
| CN105797204A (zh) | 绿原酸在制备创伤敷料中的应用 | |
| CN111420023B (zh) | 含i型胶原和透明质酸的复合物及制备和用途 | |
| JP2009269904A (ja) | 外傷、褥瘡の治療用漢方薬組成物及びその製剤の製造方法 | |
| EP1965815B1 (de) | Zusammensetzung zur wundheilung, umfassend substanzen aus dipteren-larven | |
| CN107296954A (zh) | 一种层粘连蛋白创面保护膜 | |
| CN107446018A (zh) | 促进伤口愈合的肽及其应用 | |
| CN110638999A (zh) | 一种方格星虫胶原肽在创伤修复中的应用 | |
| EP1986617A2 (en) | Extraction, preparation and use of active principles of the aloe plant to realize of self-medication devices such as aloe controlled-release gauzes, bandages, stockings, elastic bands and arch supports | |
| CN103006706B (zh) | 一种用于眼表重建的羊膜脂质体及其制备方法和应用 | |
| CN109125299A (zh) | 一种促进伤口愈合的药剂及其制备方法 | |
| RU2433171C1 (ru) | Способ получения биологически активной субстанции из эмбрионально-яичной массы для приготовления противоожоговой пластины и противоожоговая пластина на его основе | |
| CN106562953A (zh) | 羟基红花黄色素a在制备治疗糖尿病足溃疡的药物中的应用、药物及药物制备方法 | |
| RU2381810C1 (ru) | Гель-бальзам, обладающий ранозаживляющим действием | |
| RU2647458C1 (ru) | Ранозаживляющая, противовоспалительная мазь на основе чайного гриба (medusomyces gisevii lindau) | |
| CN106727282A (zh) | 一种预防和治疗糖尿病足的凝胶制剂及其制备方法 | |
| CN110559468B (zh) | 含人成纤维细胞调节培养液医用敷料贴及制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171027 |
|
| WD01 | Invention patent application deemed withdrawn after publication |